Nebraska will receive more than $200,000 as part of a multi-state settlement with Wyeth Pharmaceuticals.
Wyeth reached a $491 million settlement with the states over allegations that the drug company promoted Rapamune for unapproved uses.
As part of the settlement, $208,554.46 will be transferred into the Nebraska Medicaid program.
“Pharmaceutical companies should not profit by skirting the law,” said Attorney General Jon Bruning in a written statement released by his office. “This settlement helps to ensure these drugs are marketed properly in the future.”
According to the Attorney General’s office, Rapamune is an FDA approved kidney transplant drug prescribed to keep the body from rejecting a donor organ.